Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 26, Issue 12, Pages 917-938
Special Article

Management of Chronic Hepatitis B: Canadian Association for the Study of the Liver Consensus Guidelines

Carla S Coffin,1 Scott K Fung,2 and Mang M Ma3

1Department of Medicine, University of Calgary, Calgary, Alberta, Canada
2Department of Medicine, University of Toronto, Toronto, Ontario, Canada
3Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Received 22 July 2012; Accepted 12 August 2012

Copyright © 2012 Canadian Association for the Study of the Liver. This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (, which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes.


Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological factors. The management of CHB has become more complex with the increasing use of long-term oral nucleos/tide analogue antiviral therapies and the availability of novel diagnostic assays. Furthermore, there is often a lack of robust data to guide optimal management such as the selection of therapy, duration of treatment, potential antiviral side effects and the treatment of special populations. In November 2011, the Canadian Liver Foundation and the Canadian Association for the Study of the Liver convened a consensus conference to review the literature and analyze published data, including other international expert guidelines on CHB management. The proceedings of the consensus conference are summarized and provide updated clinical practice guidelines to assist Canadian health care providers in the prevention, diagnosis, assessment and treatment of CHB.